1. Home
  2. DKI vs BIVI Comparison

DKI vs BIVI Comparison

Compare DKI & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DKI

DarkIris Inc. Class A Ordinary Shares

N/A

Current Price

$0.43

Market Cap

8.7M

Sector

N/A

ML Signal

N/A

Logo BioVie Inc.

BIVI

BioVie Inc.

N/A

Current Price

$1.39

Market Cap

8.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DKI
BIVI
Founded
2018
2013
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.7M
8.5M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
DKI
BIVI
Price
$0.43
$1.39
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
493.4K
91.3K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.30
$0.62
52 Week High
$11.80
$9.09

Technical Indicators

Market Signals
Indicator
DKI
BIVI
Relative Strength Index (RSI) 47.67 54.55
Support Level $0.38 $1.19
Resistance Level $0.47 $1.68
Average True Range (ATR) 0.03 0.10
MACD -0.00 0.01
Stochastic Oscillator 47.37 61.54

Price Performance

Historical Comparison
DKI
BIVI

About DKI DarkIris Inc. Class A Ordinary Shares

Darkiris Inc is a comprehensive technology enterprise engaged in the development, publishing and operating of mobile digital games via various third-party digital storefronts. Its activities encompass including game design, programming and graphics, as well as distribution and operation of mobile games on various platforms. Its core product offerings are Games Development; develop, market and distribute its self-developed mobile games; and Games Publishing and Operation. It publish and operate its self-developed mobile games and mobile games it license from other game developers.

About BIVI BioVie Inc.

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Share on Social Networks: